Consequently, IFN-γ-primed MSCs have been employed as therapeutic agents in modulating T cell-related immune responses in various disease models, including experimental autoimmune encephalomyelitis (EAE) [33], renal fibrosis [34], and atopic dermatitis [35]. Here, IFNG is linked to atopic eczema.